References

List of Literature

  1. Ring, J., U. Krämer, T. Schäfer, and H. Behrendt. 2001. Why are allergies increasing? Curr Opin Immunol. 13: 701-708.
  2. Valenta, R., F. Ferreira, M. Focke-Tejkl, B. Linhart, V. Niederberger, I. Swoboda, and S. Vrtala. 2010. From allergen genes to allergy vaccines. Ann. Rev. Immunol. 28: 211-41.
  3. Bousquet, J.,. et al., Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy. 65: 1212-1221.
  4. Werfel, T,. 2009. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 129: 1878-1891.
  5. Bischoff, S. C,. Food allergies. 2007. Curr Treat Options Gastroenterol. 10: 34-43.
  6. Fang, C., C. J. Corrigan, and S. Ying. 2008. The treatment targets of asthma: from laboratory to clinic. Inflamm Allergy Drug Targets. 7: 119-128.
  7. Platts-Mills, T. A., 2007. The role of indoor allergens in chronic allergic disease.  J Allergy Clin Immunol. 119: 297-302.
  8. Hatzivlassiou, M., C. Grainge, V. Kehagia, L. Lau, and P. H. Howarth. 2010. The allergen specificity of the late asthmatic reaction. Allergy. 65: 355-358.
  9. Helbling, A., T. Hurni, U. R. Mueller, and W. J. Pichler. 2004. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy. 34 :285-290.
  10. Bischoff, S. C,. 2007. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 7: 93-104.
  11. Novak, N., T. Bieber, and S. Kraft. 2004. Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep. 4: 263-269.
  12. van Neerven, R. J., E. F. Knol, A. Ejrnaes, and P. A. Würtzen. 2006. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol. 141: 119-129.
  13. Wahn, U,. 2002. Immunotherapy in children. Curr Opin Allergy Clin Immunol. 2: 557-560.
  14. Jacobsen, L., B. Niggemann, S. Dreborg, H. A. Ferdousi, S. Halken, A. Host, A. Koivikko, L. A. Norberg, E. Valovirta, U. Wahn, and C. Moller. 2007. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62:943-948.
  15. Durham, S. R., S. M. Walker, E. M. Varga, M. R. Jacobson, F. O'Brien, W. Noble, S. J. Till, Q. A. Hamid, and K. T. Nouri-Aria. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 341: 468-475.
  16. Thomas, W. R., B. J. Hales, and W. A. Smith. 2010. House dust mite allergens in asthma and allergy. Trends Mol Med. 16: 321-328.
  17. Valenta R., P. Steinberger, M. Duchene, and D. Kraft.1996. Immunological and structural similarities among allergens: prerequisite for a specific and component-based therapy of allergy. Immunol. Cell. Biol. 74: 187-194.
  18. Radauer C., M. Bublin, S. Wagner, A. Mari, and H. Breiteneder. 2008. Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J. Allergy Clin. Immunol. 121:847-852.
  19. Harwanegg, C., S. Laffer, R. Hiller, M. W. Mueller, D. Kraft, S. Spitzauer and R. Valenta. 2003. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy. 33: 7-13.
  20. Müller, U. R., N. Johansen, A. B. Petersen, J. Fromberg-Nielsen, and G. Haeberli. 2009. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy. 64: 543-548.
  21. Sastre, J,. 2010, Molecular diagnosis in allergy. Clin Exp Allergy. 40 :1442-1460.
  22. Hansen, K. S,.  B. K. Ballmer-Weber, J. Sastre, J. Lidholm, K. Andersson, H. Oberhofer, M. Lluch-Bernal, J. Ostling, L. Mattsson, F. Schocker, S. Vieths, and L. K. Poulsen. 2009. Component-resolved in vitro diagnosis of hazelnut allergy in Europe. J Allergy Clin Immunol. 123: 1134-1141.
  23. Oldfield, W. L., M. Larché, and A. B. Kay. 2002. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 360: 47-53.
  24. Jutel, M., L. Jaeger, R. Suck, H. Meyer, H. Fiebig, and O. Cromwell. 2005. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 116: 608-613.
  25. Pauli, G., T. H. Larsen, S. Rak, F. Horak, E. Pastorello, R. Valenta, A. Purohit, M. Arvidsson, A. Kavina, J. W. Schroeder, N. Mothes, S. Spitzauer, A. Montagut, S. Galvain, M. Melac, C. Andre, L. K. Poulsen, and H. J. Malling. 2008. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 122: 951-960.
  26. Niederberger, V., F. Horak, S. Vrtala, S. Spitzauer, M. T. Krauth, P. Valent, J. Reisinger, M. Pelzmann, B. Hayek, M. Kronqvist, G. Gafvelin, H. Grönlund, A. Purohit, R. Suck, H. Fiebig, O. Cromwell, G. Pauli, M. van Hage-Hamsten, and R. Valenta. 2004. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2: 14677-14682.
  27. Creticos, P. S., J. T. Schroeder, R. G. Hamilton, S. L. Balcer-Whaley, A. P. Khattignavong, R. Lindblad, H. Li, R. Coffman, V. Seyfert, J. J. Eiden, D. Broide, and Immune Tolerance Network Group. 2006. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 355: 1445-1455.
  28. Rolland, J. M., L. M. Gardner, and R. E. O'Hehir. 2009. Allergen-related approaches to immunotherapy. Pharmacol Ther. 121: 273-284.
  29. Linhart, B., A. Hartl, B. Jahn-Schmid, P. Verdino, W.Keller, M. T. Krauth, P. Valent, F. Horak, U. Wiedermann, J. Thalhamer, C. Ebner, D. Kraft, and R. Valenta. 2005. A hybrid molecule resembling the eptitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115(5): 1010-6.
  30. Valenta, R., K. Niespodziana, M. Focke-Tejkl, K. Marth, H. Huber, A. Neubauer, and R. Valenta. 2011. Recombinant allergens: What does the future hold? J. Allergy Clin. Immunol. 127: 860-864.
  31. Edlmayr J., K. Niespodziana, B. Linhart, M. Focke-Tejkl, K. Westritschnig, S. Scheiblhofer, A. Stoecklinger, M. Kneidinger, P. Valent, R. Campana, J. Thalhamer, T. Popow-Kraupp, and R. Valenta. 2009. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J. Immunol. 182: 6298-6306.
  32. Niespodziana K., M. Focke-Tejkl, B. Linhart, V. Civaj, K. Blatt, P. Valent, M. van Hage, H. Grönlund, and R. Valenta. 2011. A hypoallergenic cat vaccine based on Fel d 1- derived peptides fused to hepatitis B PreS. J. Allergy Clin. Immunol. [Epub ahead of print].